A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells

Yong Ko, Katrim Koli, Sunandita S. Banerji, Wenhui Li, Elizabeth Zborowska, James K.V. Willson, Michael G. Brattain, Carlos L. Arteaga

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The role of transforming growth factor (TGF)-ß type II receptor (TßRII) in TGF-ß resistance and tumor progression is now well recognized. To test the effects of TßRII loss in determining malignancy, we transfected a TßRII-expressing, TGF-ß-sensitive, MCF-7 cell strain (ME24) with a tetracycline-repressible truncated TßRII (kdTßRII) construct lacking the cytoplasmic domain of the receptor. Transfection of kdTßRII into parental ME24 cells (designated ME24t6 after transfection) resulted in high expression levels of kdTßRII mRNA and cell surface protein which were reversible by tetracycline treatment. ME24t6 cells did not respond to exogenous TGF-ß1 as measured by inhibition of proliferation or fibronectin (FN) induction, indicating that the truncated TßRII acted as a dominant-negative inhibitor of both the growth inhibitory and extracellular matrix (ECM) stimulatory TGF-ß effects. Furthermore, inhibition of kdTßRII expression by tetracycline treatment led to TGF-ß1-mediated cell growth arrest in the G1 phase of cell cycle and to the accumulation of the hypophosphorylated form of retinoblastoma (Rb) protein. However, compared to parental ME24 cells, transfectants failed to show increased tumorigenicity, indicating that loss of TßRII itself is not sufficient to account for differences in the malignant properties of TßRII-expressing and non-expressing MCF-7 cell strains.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalInternational journal of oncology
Volume12
Issue number1
StatePublished - Jan 1 1998

Fingerprint

Growth Factor Receptors
MCF-7 Cells
Transforming Growth Factors
Phosphotransferases
Breast Neoplasms
Tetracycline
Transfection
Retinoblastoma Protein
Growth Inhibitors
G1 Phase
Cytoplasmic and Nuclear Receptors
Fibronectins
Extracellular Matrix
Neoplasms
Cell Cycle
Membrane Proteins
Messenger RNA
Growth

Keywords

  • Dominant-negative inhibitor
  • MCF-7 cells
  • TGF-ß
  • Tumorigenicity
  • kdTßRII

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ko, Y., Koli, K., Banerji, S. S., Li, W., Zborowska, E., Willson, J. K. V., ... Arteaga, C. L. (1998). A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells. International journal of oncology, 12(1), 87-94.

A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells. / Ko, Yong; Koli, Katrim; Banerji, Sunandita S.; Li, Wenhui; Zborowska, Elizabeth; Willson, James K.V.; Brattain, Michael G.; Arteaga, Carlos L.

In: International journal of oncology, Vol. 12, No. 1, 01.01.1998, p. 87-94.

Research output: Contribution to journalArticle

Ko, Y, Koli, K, Banerji, SS, Li, W, Zborowska, E, Willson, JKV, Brattain, MG & Arteaga, CL 1998, 'A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells', International journal of oncology, vol. 12, no. 1, pp. 87-94.
Ko, Yong ; Koli, Katrim ; Banerji, Sunandita S. ; Li, Wenhui ; Zborowska, Elizabeth ; Willson, James K.V. ; Brattain, Michael G. ; Arteaga, Carlos L. / A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells. In: International journal of oncology. 1998 ; Vol. 12, No. 1. pp. 87-94.
@article{477b130a2f04483fa5dc6800247a3ff8,
title = "A kinase-defective transforming growth factor-{\ss} receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells",
abstract = "The role of transforming growth factor (TGF)-{\ss} type II receptor (T{\ss}RII) in TGF-{\ss} resistance and tumor progression is now well recognized. To test the effects of T{\ss}RII loss in determining malignancy, we transfected a T{\ss}RII-expressing, TGF-{\ss}-sensitive, MCF-7 cell strain (ME24) with a tetracycline-repressible truncated T{\ss}RII (kdT{\ss}RII) construct lacking the cytoplasmic domain of the receptor. Transfection of kdT{\ss}RII into parental ME24 cells (designated ME24t6 after transfection) resulted in high expression levels of kdT{\ss}RII mRNA and cell surface protein which were reversible by tetracycline treatment. ME24t6 cells did not respond to exogenous TGF-{\ss}1 as measured by inhibition of proliferation or fibronectin (FN) induction, indicating that the truncated T{\ss}RII acted as a dominant-negative inhibitor of both the growth inhibitory and extracellular matrix (ECM) stimulatory TGF-{\ss} effects. Furthermore, inhibition of kdT{\ss}RII expression by tetracycline treatment led to TGF-{\ss}1-mediated cell growth arrest in the G1 phase of cell cycle and to the accumulation of the hypophosphorylated form of retinoblastoma (Rb) protein. However, compared to parental ME24 cells, transfectants failed to show increased tumorigenicity, indicating that loss of T{\ss}RII itself is not sufficient to account for differences in the malignant properties of T{\ss}RII-expressing and non-expressing MCF-7 cell strains.",
keywords = "Dominant-negative inhibitor, MCF-7 cells, TGF-{\ss}, Tumorigenicity, kdT{\ss}RII",
author = "Yong Ko and Katrim Koli and Banerji, {Sunandita S.} and Wenhui Li and Elizabeth Zborowska and Willson, {James K.V.} and Brattain, {Michael G.} and Arteaga, {Carlos L.}",
year = "1998",
month = "1",
day = "1",
language = "English (US)",
volume = "12",
pages = "87--94",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - A kinase-defective transforming growth factor-ß receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells

AU - Ko, Yong

AU - Koli, Katrim

AU - Banerji, Sunandita S.

AU - Li, Wenhui

AU - Zborowska, Elizabeth

AU - Willson, James K.V.

AU - Brattain, Michael G.

AU - Arteaga, Carlos L.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The role of transforming growth factor (TGF)-ß type II receptor (TßRII) in TGF-ß resistance and tumor progression is now well recognized. To test the effects of TßRII loss in determining malignancy, we transfected a TßRII-expressing, TGF-ß-sensitive, MCF-7 cell strain (ME24) with a tetracycline-repressible truncated TßRII (kdTßRII) construct lacking the cytoplasmic domain of the receptor. Transfection of kdTßRII into parental ME24 cells (designated ME24t6 after transfection) resulted in high expression levels of kdTßRII mRNA and cell surface protein which were reversible by tetracycline treatment. ME24t6 cells did not respond to exogenous TGF-ß1 as measured by inhibition of proliferation or fibronectin (FN) induction, indicating that the truncated TßRII acted as a dominant-negative inhibitor of both the growth inhibitory and extracellular matrix (ECM) stimulatory TGF-ß effects. Furthermore, inhibition of kdTßRII expression by tetracycline treatment led to TGF-ß1-mediated cell growth arrest in the G1 phase of cell cycle and to the accumulation of the hypophosphorylated form of retinoblastoma (Rb) protein. However, compared to parental ME24 cells, transfectants failed to show increased tumorigenicity, indicating that loss of TßRII itself is not sufficient to account for differences in the malignant properties of TßRII-expressing and non-expressing MCF-7 cell strains.

AB - The role of transforming growth factor (TGF)-ß type II receptor (TßRII) in TGF-ß resistance and tumor progression is now well recognized. To test the effects of TßRII loss in determining malignancy, we transfected a TßRII-expressing, TGF-ß-sensitive, MCF-7 cell strain (ME24) with a tetracycline-repressible truncated TßRII (kdTßRII) construct lacking the cytoplasmic domain of the receptor. Transfection of kdTßRII into parental ME24 cells (designated ME24t6 after transfection) resulted in high expression levels of kdTßRII mRNA and cell surface protein which were reversible by tetracycline treatment. ME24t6 cells did not respond to exogenous TGF-ß1 as measured by inhibition of proliferation or fibronectin (FN) induction, indicating that the truncated TßRII acted as a dominant-negative inhibitor of both the growth inhibitory and extracellular matrix (ECM) stimulatory TGF-ß effects. Furthermore, inhibition of kdTßRII expression by tetracycline treatment led to TGF-ß1-mediated cell growth arrest in the G1 phase of cell cycle and to the accumulation of the hypophosphorylated form of retinoblastoma (Rb) protein. However, compared to parental ME24 cells, transfectants failed to show increased tumorigenicity, indicating that loss of TßRII itself is not sufficient to account for differences in the malignant properties of TßRII-expressing and non-expressing MCF-7 cell strains.

KW - Dominant-negative inhibitor

KW - MCF-7 cells

KW - TGF-ß

KW - Tumorigenicity

KW - kdTßRII

UR - http://www.scopus.com/inward/record.url?scp=0031974364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031974364&partnerID=8YFLogxK

M3 - Article

C2 - 9454891

AN - SCOPUS:0031974364

VL - 12

SP - 87

EP - 94

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -